Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Abstract

<div>Abstract<p><i>PIK3CA</i> is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%–25% of gastric cancers display activating <i>PIK3CA</i> mutations, including 80% of Epstein–Barr virus–associated GCs. Small molecules, including pan-PI3K and dual PI3K/mTOR inhibitors, have shown moderate success clinically, due to broad on-target/off-tissue effects. Thus, isoform-specific and mutant selective inhibitors have been of significant interest. However, drug resistance is a problem and has affected success of new drugs. There has been a concerted effort to define mechanisms of resistance and identify potent combinations in many tumor types, though gastric cancer is comparatively understudied. In this study, we identified modulators of the response to the PI3Kα-specific inhibitor, BYL719, in <i>PIK3CA</i>-mutant GCs. We found that loss of <i>NEDD9</i> or inhibition of BCL-XL conferred hypersensitivity to BYL719, through increased cell-cycle arrest and cell death, respectively. In addition, we discovered that loss of <i>CBFB</i> conferred resistance to BYL719. <i>CBFB</i> loss led to upregulation of the protein kinase PIM1, which can phosphorylate and activate several overlapping downstream substrates as AKT thereby maintaining pathway activity in the presence of PI3Kα inhibition. The addition of a pan-PIM inhibitor re-sensitized resistant cells to BYL719. Our data provide clear mechanistic insights into PI3Kα inhibitor response in <i>PIK3CA</i>-mutant gastric tumors and can inform future work as mutant-selective inhibitors are in development for diverse tumor types.</p>Implications:<p>Loss of either NEDD9 or BCL-XL confers hypersensitivity to PI3K-alpha inhibition whereas loss of CBFB confers resistance through a CBFB/PIM1 signaling axis.</p></div>